Abstract: Purpose/Aim of the study: BRAFV600E is an oncogenic point mutation in the MAPK/ERK signaling pathway, which is important for cell proliferation and migration. It has been found to be associated with several malignancies and has also been found in significant proportions of patients with Langerhans cell histiocytosis. A recent mouse model which introduces the BRAFV600E mutations only into dendritic cell precursors results in a clinical picture very similar to human sarcoidosis. We therefore hypothesized that somatic BRAFV600E mutations may play a role in granuloma formation and/or maintenance in all or a subset of patients with sarcoidosis. Materials and methods: 28 diagnostic lymph node samples and 1 diagnostic lung parenchyma sample of patients with confirmed sarcoidosis were identified. Paraffin sections including positive and negative controls were stained using pre-diluted Ventana Medical Systems anti-BRAF V600E (VE1) mouse monoclonal antibody and processed on an automated Ventana Benchmark Ultra immunostainer. Slides were analyzed by two independent experts. Results: BRAFV600E immunostaining was negative in all 29 cases. Conclusions: Sarcoidosis is not associated with the BRAFV600E mutation and is very unlikely to be associated with other less common BRAF mutations not tested for in this study. Future studies addressing a potential role of other somatic mutations in cell proliferation and migration pathways are warranted.
ABOUT THE AUTHORS
The Sarcoidosis Program at Mount Sinai Hospital in New York is exploring the biology of the disease in order to increase our understanding of how the condition itself develops and advances.
We are also studying the anatomical and functional heterogeneity of dendritic cells (DC) in the human lung. After characterizing important functional distinctions between the major classical DC subsets in the steady state human lung, the focus now is on the diseased human lung, particularly sarcoidosis. In addition, we are conducting correlative immunophenotyping studies for various clinical studies.
PUBLIC INTEREST STATEMENT
Sarcoidosis is a mysterious disease that affects a lot of people around the world. Even after decades of active research it is still unclear what causes this disease.
Recently researchers have created a mouse model in which they introduced a certain mutation (called BRAFV600E) only in certain immune cells of these mice, and the result was that the mice developed a disease state that looks very similar to sarcoidosis.
It is therefore possible that the BRAFV600E mutation in these immune cells has something to do with how sarcoidosis develops.
We therefore tested whether human sarcoidosis disease tissue carries this mutation. We did not find evidence that it does.
Introduction
BRAF is a protein kinase in mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway signaling. The pathway is important for cell proliferation and migration processes. The point mutation BRAFV600E leads to a constitutive activation of ERK and MEK resulting in dysregulated cellular proliferation and malignant transformation. Independent studies have identified the oncogenic BRAFV600E mutation in an expanding variety of malignancies (Machnicki & Stoklosa, 2014) . The BRAF point mutation V600E has also been identified in a significant percentage of human Langerhans Cell Histiocytosis (LCH) specimens (35 out of 61 samples (57%) (Badalian-Very et al., 2010) , 9 out of 16 samples (56%) (Satoh et al., 2012) and 34 out of 89 samples (38%) (Sahm et al., 2012) . The first study used mass spectrometric genotyping and pyrosequencing from paraffinembedded tissues, the second used fresh flow cytometry sorted CD1a+ vs. CD1a-cells from LCH granulomas for pyrosequencing (Roche GS FLX 454) while the third study used a BRAFV600E mutation-specific antibody on paraffin-embedded tissue. Of the 61 cases in the first study 7 cases represented the specific and separate disease entity of adult patients exhibiting smoking related single organ involvement, which is termed pulmonary Langerhans cell histiocytosis (PLCH). 2 of the 5 cases were positive for BRAFV600E (Badalian-Very et al., 2010) , a finding confirmed by next generation sequencing in another study (2/5 or 40%) (Yousem, Dacic, Nikiforov, & Nikiforova, 2013) , as well as by two further studies which both included both PLCH and extrapulmonary LCH (7/25 or 28% BRAFV600E positive cases in PLCH and 19/54 or 35% in extrapulmonary LCH for the first study (Roden et al., 2014) , and 12/19 or 63% BRAFV600E positive cases in PLCH and 6/19 or 32% in extrapulmonary LCH for the second study (Chilosi et al., 2014) . A study looking at various other histiocytic diseases found a high prevalence of the BRAFV600E mutation in LCH (38%, 11/29) and Erdheim-Chester Disease (ECD) (54%, 13/24), but not in other histiocytic diseases like Rosai-Dorfman disease, juvenile xanthogranuloma (JXG), histiocytic sarcoma, xanthoma disseminatum, interdigitating dendritic cell sarcoma and necrobiotic xanthogranuloma (Haroche et al., 2012) . More recent publications did find BRAFV600E mutation in a case of indeterminate cell tumor and a case of interdigitating DC sarcoma (IDCS) (Fedoriw et al., 2014) , and in cases of histiocytic sarcoma (62.5%, 5/8), follicular dendritic cell sarcoma (18.5%, 5/27) and giant cell tumors (6.7%, 2/30) (Go et al., 2014) . In cases of mixed histiocytosis (LCH and ECD) in the same patient, a recent study established an association linked to the BRAFV600E mutation (Hervier et al., 2014) . BRAFV600 point mutations have also been found in a variety of brain tumors with varying frequencies (Berghoff & Preusser, 2014) . Vemurafenib, a monoclonal antibody against mutated BRAF, is successfully being used in BRAFV600E-positive malignant melanoma (Bollag et al., 2010) and hairy cell leukemia (Dietrich et al., 2012) . A recent case report on three patients with advanced multisystemic ECD, two of which had concurrent LCH, showed a dramatic response to vemurafenib treatment (Haroche et al., 2013) .
A recent publication, having found BRAFV600E in 64 out of 100 LCH patients, characterized BRAFV600E expression in precursor cells vs. differentiated dendritic cells as clinical "high risk" vs. "low risk" groups (Berres et al., 2014) and proposed to reclassify LCH, JXG and ECD as inflammatory myeloid neoplasms (Berres, Allen, & Merad, 2013) .
Two different mouse models were generated to evaluate the differential effects of expression of mutated BRAFV600E starting in DC precursors vs. only in differentiated dendritic cells. Expression of the BRAFV600E conditional allele was enforced either under the Langerin promoter or the CD11c promoter, resulting in conditional expression of BRAFV600E either only in differentiated tissue-resident DCs (BRAFV600E Langerin ) or also in committed DC progenitor cells ( BRAFV600E CD11c ). The group of mice which expressed BRAFV600E in committed DC progenitor cells developed an aggressive LCHlike disease phenotype with high penetrance and associated mortality, whereas those expressing BRAFV600E only in differentiated tissue-resident DCs only developed mild pathologic findings mainly in the liver and lung (Berres et al., 2014) . The group of BRAFBRAFV600E CD11c mice histologically developed severe hepatosplenomegaly, lymphadenopathy and multiorgan infiltration in lungs, skin, liver and spleen with granulomatous lesions comprised of histiocytes, multinucleated giant cells, macrophages, T cells, NK cells, B cells and regulatory T cells (Berres et al., 2014) . The local cytokine expression profile of these lesions showed high levels of Il-6, Il-10, IFN-γ and TGF-β (Berres et al., 2014) . Overall, the cellular composition and cytokine expression profile of the granulomatous lesions in these BRAFV600E CD11c mice is very similar to that of sarcoidal granulomatous lesions (Bergeron et al., 1997; Iannuzzi, Rybicki, & Teirstein, 2007; Ma, Gal, & Koss, 2007) . On the contrary, newly diagnosed sarcoidosis has been reported as a complication of vemurafenib therapy for malignant melanoma in two patients (Adam et al., 2013) . Another patient with chemotherapy-refractory metastatic melanoma developed sarcoidosis after treatment with the CTLA-4 inhibitory antibody ipilimumab, which improved after corticosteroid therapy. The progressive metastatic disease was treated with vemurafenib, which provided temporary improvement of the metastatic burden (Wilgenhof et al., 2012) . Dysregulation of MAP-kinase pathways has been found in response to microbial products in BAL cells of patients with sarcoidosis compared to controls (Rastogi et al., 2011) .
Given the striking resemblance of the BRAFV600E CD11c mouse model histology and cytokine expression profiles with human sarcoidosis we hypothesized that somatic BRAFV600E mutations could play a pathogenetic role in granuloma formation or maintenance in either all or a subset of patients with sarcoidosis.
Materials and methods

Case selection
The study was approved by the Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects (PPHS; IRB#15-01127). Sample selection is illustrated in Figure 1 . Sarcoidosis cases were identified via search of pathology records from October 2010 through October 2014 using search terms of "non-necrotizing granulomas," "lymph node" and "lung". Only resection or large samples such as lymph nodes obtained via mediastinoscopy were included in order to maximize the number of granulomas present in a specimen. Transbronchial, endobronchial, core biopsy and cytology specimens were excluded. 241 cases were retrieved. Cases were excluded if necrotizing granulomas were also present or if the granulomas were found in specimens otherwise submitted for resection of malignancy. Cases with positive tissue culture results were also excluded. Of the remaining 45 cases 9 patients did not meet clinico-radiographic criteria for sarcoidosis in clinical data review, 4 cases were found to have positive fungal stains and 2 cases positive mycobacterial stains. The remaining 30 cases were determined to represent unambiguous cases of sarcoidosis from a clinical standpoint, had negative Ziehl-Neilson and Gomori Methenamine Silver (GMS) stains to evaluate for the presence of mycobacteria and fungi, and had no history of concomitant malignancy.
Anti-BRAF V600E immunostaining
Anti-BRAF V600E immunostaining was performed on freshly cut 4 micrometer tissue sections from formalin-fixed paraffin-embedded (FFPE) tissue blocks using pre-diluted Ventana Medical Systems anti-BRAF V600E (VE1) mouse monoclonal antibody and run on an automated Ventana Benchmark Ultra immunostainer (Ventana Medical Systems, Tucson, AZ). Antibody incubation time was 64 min. Colorectal carcinoma with a known BRAF V600E mutation was used as a positive control (Figure 2(f) , insert). Background lymphocytes and normal tissue were used as a negative tissue control. A separate negative control with omitted antibody showed no chromogen detection. VE1 antibody staining was interpreted as positive when clear cytoplasmic staining was present anywhere within the granulomas. The stain was interpreted as negative if there was no staining, isolated nuclear staining or faint diffuse staining. Specimen analysis was performed by two independent observers, a pulmonary pathologist and a physician scientist/pulmonologist. Inter-observer agreement was 100%.
Results
BRAF antibody staining was interpreted in 29 of 30 cases. One case was found to contain no remaining granulomas in the tissue block and could not be evaluated. Evaluable cases consisted of 23 mediastinal lymph nodes, 3 cervical lymph nodes, 1 inguinal lymph node, 1 supraclavicular lymph node and 1 lung wedge resection performed for excision of a radiographic nodule. Hematoxylin and Eosin (H&E) stained slides on all specimens demonstrated numerous well-formed non-necrotizing granulomas with varying degrees of associated fibrosis. The lung specimen showed a nodular cluster of coalescing confluent non-necrotizing granulomas. Single or small clusters of granulomas were also identified within the remaining lung parenchyma. Additional Ziehl-Neilson and Gomori Methenamine Silver (GMS) stains were performed on all cases to evaluate for the presence of mycobacteria or fungi and were negative in all cases.
BRAF immunostaining was negative in all cases. Small areas of pseudo-positive staining as seen in Figure 2 (e) and (f) on higher magnification correspond to pigmented macrophages which lack diffuce strong cytoplasmic staining associated with BRAFV600E mutation but indicate phagocytic foreign pigmented material ingestion.
Discussion
The etiology of sarcoidosis is unclear. The BRAFV600E CD11c mouse model that was recently generated to evaluate the systemic effects of expression of mutated BRAFV600E starting with committed DC progenitor cells showed histopathologic and gene expression features very similar to sarcoidosis (Berres et al., 2014) . We therefore explored the hypothesis that somatic BRAFV600E mutations in committed DC progenitor cells or other cell lineages involved in granuloma formation and maintenance contribute to the pathogenesis of sarcoidosis. If BRAF mutations were to be pathogenetically linked to sarcoidosis in all or a subset of patients, mutational analysis could be incorporated into the diagnostic workup of patients with sarcoidosis and treatment with vemurafenib could be tested in a clinical trial setting for patients with associated BRAF mutations. Unfortunately, we did not find any positive BRAF immunostainings in our sample set. An important limitation of our study is sample size. The frequency of BRAF alterations in general and the BRAFV600E mutation in particular varies depending on the associated specific disease entity, but generally the BRAFV600E frequencies range from 20 to 96% for various CNS tumors (Berghoff & Preusser, 2014) , around 38-54% for Langerhans cell histiocytosis (Haroche et al., 2012; Sahm et al., 2012; Satoh et al., 2012) , 82% for ErdheimChester-Disease (Hervier et al., 2014) to close to 100% for hairy cell leukemia (Andrulis, Penzel, Weichert, von Deimling, & Capper, 2012) . Assuming very conservatively that BRAFV600E mutations are pathophysiologically relevant in only 10% of patients with sarcoidosis, which would be lower than other reported disease associations, screening 29 patients statistically results in a less than 5% risk of not detecting an existing association (0.9 29 ). It seems unlikely that sampling error due to anatomic heterogeneity of BRAFV600E mutational status will lead to false negative immunostaining when single nodules per patient are examined, as a study assessing multiple nodules per patient with pulmonary Langerhans cell histiocytosis (PLCH) demonstrated concordance of BRAFV600E mutation occurrence for all cases, i.e. either all stained nodules were positive or negative for the BRAFV600E mutation (Yousem et al., 2013) .
Another limitation of this study is that we only examined the BRAFV600E mutation and not all other known and unknown sequence variations in the BRAF gene. In contrast to detection of BRAFV600E, which is possible via the commercial immunohistochemistry antibody used in this study, more costly techniques like DNA isolation from sarcoidosis tissue followed by pyrosequencing or Polymerase Chain reaction (PCR) based approaches are necessary to reliably detect other BRAF mutations. However, most of the detected BRAF mutations in a recent study were BRAFV600E (9 out of 11 patients with BRAF mutations (Satoh et al., 2012) ). A study characterizing PLCH samples with next generation sequencing for mutations in 46 cancer genes found only BRAFV600E mutations in 40% of cases, albeit with the limited sample size of 5 (2/5) (Yousem et al., 2013) . This high ratio of BRAFV600E to other BRAF mutations makes it overall extremely unlikely that a sample size of 29 samples would include only cases of other BRAF mutations without any cases of BRAFV600E. We therefore believe that, even without specifically assessing for other BRAF mutations, non-BRAFV600E mutations are unlikely to be involved in sarcoidal granuloma formation and/or maintenance. Since the immunohistochemical antibody detects expressed mutant protein negative BRAFV600E staining is possible if the amount of mutant protein expressed by cells carrying the mutation is below the detection threshold. Lastly, the sensitivity of the immunohistochemical detection method in formalin-fixed, paraffin-embedded tissue samples itself constitutes a limitation. Pyrosequencing of DNA extracted from granulomatous tissue samples is more sensitive, but the strongly positive staining of the colon carcinoma positive controls makes it unlikely that pathogenetically relevant mutations would stain falsely negative in all sarcoidosis samples. Furthermore, two recent studies independently demonstrated a high degree of correlation between IHC staining and BRAFV600E mutational status by sequencing analysis of the same sample (Chilosi et al., 2014; Roden et al., 2014) .
Conclusion
In conclusion, sarcoidosis is not associated with somatic BRAFV600E mutations and is very unlikely to be associated with other less common BRAF mutations not tested for by this study. Future studies utilizing pyrosequencing and PCR-based techniques to address other somatic mutations in cell proliferation and migration pathways are still warranted.
